PharmTech Drug Digest 11.20
News|Articles|December 12, 2013

Moberg Pharma Acquires OTC Brands from Bayer

Author(s)Melanie Sena

Moberg Pharma will acquire three OTC brands from Bayer HealthCare.

Moberg Pharma AB, a Swedish pharmaceutical company,  has signed a deal to acquire three over-the-coutner brands in the US from Bayer HealthCare. The acquired portfolio includes: Domeboro, a topical astringent used for relieving itch and minor skin irritations; Vanquish, an internal analgesic; and Fergon, an iron supplement. The brands will be sold through Moberg’s current channel, primarily in chain drugstores and mass retailers, such as Walmart. The transaction is expected to close before the end of 2013.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.